Country-specific aspects of indication and safety of current therapies

The approval of some immunotherapies in MS differs in Switzerland sometimes significantly from those of neighboring countries. A group of neurologists, with the participation of the Swiss MS Society and the SNS, has therefore drawn up recommendations in the sense of a therapeutic consensus.